alpelisib plus fulvestrant in pik3ca mutated hormone receptor positive advanced breast cancer after a cdk4 6 inhibitor bylieve one cohort of a phase 2 multicentre open label non comparative study the lancet oncology
haines educational science catalogue 2018 by haines educational issuu